EUCTR2020-000250-94-IT进行中（未招募）1 期
Mutation-specific therapy for the long QT syndrome - MAST2
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Informed consent: it is requested that the partipants understand the nature of the study and can give their voluntary conset after being fully informed, after having received satisfying replies to their questions regarding the study, and all the authorizations according to local requirements. The informed consent form will previously be approved by the local Ethics Committee e will have to be dated and signed before enrollment in the study, in accordance with the rules of Good Clinica Practice (ICH-GCP) and the local requirements.
- •Age and gender: participants of both the male and female sex aged between 18 and 65 years will be included
- •Mutations: the study will enrol patients with LQT2, i.e., with pathogenic mutations on the KCNH2 gene, that present such functional characterization that classifies them as class II mutations, namely mutations that cause a trafficking defect. This characterization includes, but is not limited to, patch clamp data in single cells, immunofluorescence data, positive reactions to drugs that correct the trafficking defect in vitro. Some examples of trafficking-deficient variants in our pateint database are: KCNH2-p.Y43C, KCNH2-p.A78P, KCNH2-p.R534C, KCNH2-p.A561V, KCNH2-p.W568C, KCNH2-p.G572S, KCNH2-p.P596L, KCNH2-p.G601S, KCNH2-p.G604S, KCNH2-p.V612A, KCNH2-p.T613M, KCNH2-p.A614V, KCNH2-p.N629S, KCNH2-p.N633S, KCNH2-p.T634I, KCNH2-p.S641F, KCNH2-p.V644F, KCNH2-p.R752W, KCNH2-p.F805S, KCNH2-p.S818L, KCNH2-p.R823W, KCNH2-p.N861H, KCNH2-p.R863*, KCNH2-p.W927*, KCNH2-p.W1001*, KCNH2-p.R1014*. Other variants that belong to the same class of mutations will inevitably be detected in the next years.
- •Consent of the patient to not participate in any other clinical study during the entire period of participation in the present study
- •Women with child-bearing potential (pre-menopausal women, less than two years after start of menopause and women who are not surgically sterile) must use a highly effective contraceptive method from 30 days before enrollment in the study until 28 days after the last administration of study drug. It is specified that the sole use of hormonal contraception, both oral, injectable, transdermic and implantable cannot be considered an effective contraceptive method. Orkambi (Lumacaftor/ivacaftor) may reduce the exposure to the hormonal contraceptives and possibly cause their ineffectiveness. Male patients with a female partner with child-bearing potential must use 2 forms of contraception (one of which should be a double-barrier method) from enrolment in the study until 28 days after the last administration of study drug. Highly effective contraceptive methods are: i) abstinence, ii) surgical sterilization (=6 months post-surgery), iii) intrauterine device or intrauterine system, iv) oral contraceptives combined with a barrier method, v) double-barrier method (e.g., male condom or diaphragm with vaginal spermicides).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Absence of one or more of the preceeding inclusion criteria
- •Hypersensitivity to the active substance (to one or both active substances) or to one of the excipients.
- •Pregnancy (established before enrollment by positive urine pregnancy test in potentially fertile women) or breastfeeding
- •Participation in a clinical study in whch an experimental drugs has been administered less than 30 days or less than 5 half-lives before the present study drug
- •Any clinical condition that in the opinion of the investigator causes the patients not to be suitable for the study and/or that may involve an unreasonable/significant risk for the participants, thereby changing the interpretation of that data and affecting the continuation of the study
- •Other important cardiac diseases and in particular: cardiomyopathies and myocarditis, pericardial diseases, other associated channelopathies, ischemic heart disease, heart failure, pulmonary heart disease, severe valuvulopathies, rhythm alterations such as atrial fibrillation or atrial flutter, complete right or left bundle branch block, advanced atrio-ventricular blocks, uncontrolled arterial hypertension on beta-blocker therapy
- •Significant extracardiac diseases and in particular:
- •orenal failure. In accordance with the SmPC, patients with severe (estimated GFR <30 mL/min/1.73 m2) and moderate (estimated GFR 30-60 mL/min/1.73 m2) renal impairment at screening are excluded
- •oimpairment of liver function. In accordance with the SmPC, patients with severe (Child-Pugh Class C) and moderate (Child-Pugh Classe B) liver function impairment are excluded
- •oimportant diseases of the respiratory system and in particular: any pulmonitis, obstructive bronchopulmonary disease with FEV1 <80%, asthmatic bronchitis, infiltrative lung disease, lung emboly, pulmonary hypertension, idiopathic pulmonary fibrosis, pneumothorax, neoplasms of lungs and pleura
- •oimportant neurological diseases and in particular: epilepsy, cerebral hemorrhage, stroke, multiple sclerosis, cerebral tumours, cerebral or spinal traumas, Parkinson’s disease, cognitive deterioration and Alzheimer’s disease
- •Chronic use of therapies other than beta-blocker treatment and intake of any potassium/magnesium supplement that the patient may use chronically or intermittently (oral contraceptives are allowed, but must be interrupted during the study).
研究者
相似试验
已完成
2 期
Mutation-specific Therapy for the Long QT SyndromeLong QT SyndromeNCT04581408Istituto Auxologico Italiano16
Unknown
不适用
Metabolism of Patients With Genetically Caused Cardiac ArrhythmiaLong QT SyndromeNCT02775513University of Copenhagen50
Unknown
不适用
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.Romano-Ward SyndromeLong QT SyndromeCompulsive BehaviorHealthy IndividualsNCT04715256Biotrial100
已完成
不适用
Long QT Syndrome-Population Genetics and Cardiac StudiesCardiovascular DiseasesHeart DiseasesVentricular ArrhythmiaLong QT SyndromeNCT00005176University of Rochester2,125
进行中（未招募）
1 期
Genetic characteristics of the Long QT Syndrome that appears with certain pharmacological treatmentsDrug-induced Long QT SyndromeEUCTR2018-000564-28-ESInstitut de Recerca H. de la Santa Creu i Sant Pau - IIB Sant Pau120